ValuEngine downgraded shares of Endologix, Inc. (NASDAQ:ELGX) from a sell rating to a strong sell rating in a report released on Friday.

Other research analysts have also issued research reports about the company. Stifel Nicolaus reaffirmed a buy rating and set a $5.50 price target (up previously from $5.00) on shares of Endologix in a research report on Monday, June 5th. Stephens lowered Endologix from an overweight rating to an equal weight rating and set a $6.00 price target on the stock. in a research report on Thursday, May 18th. Royal Bank Of Canada reaffirmed a hold rating and set a $5.00 price target on shares of Endologix in a research report on Monday, July 31st. Zacks Investment Research lowered Endologix from a strong-buy rating to a hold rating in a research report on Tuesday, July 25th. Finally, BMO Capital Markets reaffirmed a hold rating and set a $5.00 price target on shares of Endologix in a research report on Thursday, May 18th. Two analysts have rated the stock with a sell rating and eleven have issued a hold rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $6.28.

Endologix (NASDAQ ELGX) traded up 1.89% during trading on Friday, reaching $4.31. The company had a trading volume of 803,682 shares. The company has a 50 day moving average price of $4.55 and a 200 day moving average price of $5.69. Endologix has a 52-week low of $4.08 and a 52-week high of $13.30. The company’s market capitalization is $359.60 million.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. The firm had revenue of $48.60 million for the quarter, compared to analyst estimates of $47.58 million. Endologix had a negative return on equity of 46.32% and a negative net margin of 40.77%. The business’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS. On average, equities analysts forecast that Endologix will post ($0.62) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Lowers Endologix, Inc. (ELGX) to Strong Sell” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/04/valuengine-lowers-endologix-inc-elgx-to-strong-sell.html.

Several hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers increased its holdings in shares of Endologix by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 95,581 shares of the medical instruments supplier’s stock worth $465,000 after acquiring an additional 381 shares during the last quarter. Kopp Investment Advisors LLC increased its holdings in shares of Endologix by 11.5% during the 2nd quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock worth $107,000 after acquiring an additional 2,270 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Endologix by 4.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 66,890 shares of the medical instruments supplier’s stock worth $325,000 after acquiring an additional 2,738 shares during the last quarter. American International Group Inc. increased its holdings in shares of Endologix by 7.1% during the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock worth $361,000 after acquiring an additional 3,290 shares during the last quarter. Finally, AXA increased its holdings in shares of Endologix by 0.4% during the 1st quarter. AXA now owns 962,787 shares of the medical instruments supplier’s stock worth $6,971,000 after acquiring an additional 3,532 shares during the last quarter.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.